Stockscreener 앱 받기
41.94
9.22%
3.54
시간 외 거래:
41.80
-0.14
-0.33%
전일 마감가:
$38.40
열려 있는:
$38.72
하루 거래량:
1.23M
Relative Volume:
1.64
시가총액:
$1.56B
수익:
$272.30M
순이익/손실:
$-5.14M
주가수익비율:
-256.51
EPS:
-0.1635
순현금흐름:
$42.76M
1주 성능:
+16.82%
1개월 성능:
+34.38%
6개월 성능:
-5.52%
1년 성능:
+37.92%
1일 변동 폭
$38.52
$42.47
1주일 범위
$35.50
$42.47
52주 변동 폭
$28.54
$54.85
Harrow Inc Stock (HROW) Company Profile
명칭
Harrow Inc
전화
615.733.4731
주소
1A BURTON HILLS BLVD, NASHVILLE, CA
Compare HROW vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HROW
Harrow Inc
|
41.94 | 1.45B | 272.30M | -5.14M | 42.76M | -0.1635 |
TAK
Takeda Pharmaceutical Co Adr
|
15.42 | 49.83B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
8.87 | 40.04B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.56 | 39.23B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
77.26 | 33.52B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
551.47 | 23.33B | 3.17B | 1.29B | 1.01B | 27.09 |
Harrow Inc Stock (HROW) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-11 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-06-12 | 개시 | BTIG Research | Buy |
| 2025-06-10 | 개시 | William Blair | Outperform |
| 2025-02-06 | 개시 | H.C. Wainwright | Buy |
| 2024-12-04 | 재확인 | B. Riley Securities | Buy |
| 2024-04-11 | 개시 | Craig Hallum | Buy |
| 2022-09-08 | 재개 | B. Riley Securities | Buy |
| 2021-10-14 | 재개 | B. Riley Securities | Buy |
| 2021-09-24 | 개시 | Aegis Capital | Buy |
| 2021-07-02 | 개시 | Ladenburg Thalmann | Buy |
모두보기
Harrow Inc 주식(HROW)의 최신 뉴스
Is Harrow, Inc. (HROW) A Good Stock To Buy Now? - Yahoo Finance
Harrow Adds Another Piece To Ophthalmology Strategy - Benzinga
HROW Stock Rises on Relaunch of Ophthalmology Drug Verkazia in the US - TradingView
HROW Stock Rips Higher As Traders Digest Mixed Quarter - timothysykes.com
Analysts Are Bullish on Top Healthcare Stocks: Harrow Health (HROW), GeneDx Holdings (WGS) - The Globe and Mail
Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic - GlobeNewswire
Harrow Inc. Q1 2026 Earnings: Significant EPS Miss Triggers Stock DeclineBook Value Growth - newsline.com
HARROW INC (HROW) Stock Chart - ChartMill
What Does Cantor Fitzgerald Think About Harrow (HROW) After Cutting Its Price Target? - Insider Monkey
Harrow Health Inc stock (US4158581094): Ophthalmology player trades below analyst targets amid secto - AD HOC NEWS
Harrow Inc. (HROW) Q1 2026 Earnings: Significant Earnings Miss Despite Positive Stock ReactionPeak Earnings Alert - newsline.com
William Blair Maintains Harrow(HROW.US) With Buy Rating - Moomoo
Harrow Health Releases June 2026 Investor Presentation Update - TipRanks
Harrow files Regulation FD disclosure to furnish June 2026 corporate presentation - TradingView
Harrow (NASDAQ: HROW) posts June 2026 corporate investor presentation - Stock Titan
Top 5 Small Cap Stocks With Huge Growth Potential - Insider Monkey
Harrow Health earnings on deck: Can branded drugs offset California exit? - Investing.com Nigeria
Harrow Inc. Q1 2026 Earnings: EPS Misses Estimates by Wide Margin, Stock DeclinesProfit Cycle Analysis - thelegaladvocate.com
HROW News | HARROW INC (NASDAQ:HROW) - ChartMill
Harrow Inc. (HROW) Advances 2.79% as Stock Approaches Key ResistanceLow Vol ETF - thelegaladvocate.com
Harrow Inc. (HROW) Q1 2026 Earnings: Wider-than-Expected Loss Triggers Stock RallyRevenue Per Share - thelegaladvocate.com
Harrow Inc. Q1 2026 Earnings: EPS Misses Estimates Significantly, Stock Rises Despite LossesEarnings Revision Report - newsline.com
Harrow to Present at William Blair’s 46th Annual Growth Stock Conference - GlobeNewswire
HROW Q1 2026 Earnings: EPS Misses Estimates Significantly as Company Navigates Operational ChallengesCapex Guidance - newsline.com
Harrow (HROW) Is Up 6.8% After Reaffirming 2026 Revenue Outlook Despite Wider Q1 LossesWhat's Changed - simplywall.st
Harrow Inc. (HROW) Q1 2026 Earnings: Significant EPS Miss Amid Operational ChallengesOperating Margin Analysis - newsline.com
Harrow Inc. Q1 2026 Earnings: Pharmaceutical Firm Misses EPS Estimates by Wide MarginAnalyst Coverage Count - thelegaladvocate.com
Harrow Inc (HROW) Shares Surge 6.8% -- What GF Score of 82 Tells Investors - GuruFocus
Why B.Riley Reduced Harrow, Inc. (HROW) Price Target Despite Long-Term Optimism - Insider Monkey
Harrow: Demand Keeps It Interesting, Valuation Keeps It A Hold - Seeking Alpha
Harrow, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:HROW) 2026-05-19 - Seeking Alpha
Harrow director Lauren Silvernail buys $31,000 in company stock By Investing.com - Investing.com Nigeria
Harrow director Adrienne Graves buys $31,070 in company stock By Investing.com - Investing.com Nigeria
Harrow director Lauren Silvernail buys $31,000 in company stock - Investing.com India
Insider Buying: Adrienne Graves Acquires Shares of Harrow Inc (H - GuruFocus
5 Best Small Cap Pharma Stocks to Buy Right Now - Insider Monkey
Harrow director Adrienne Graves buys $31,070 in company stock - Investing.com
Harrow (HROW) director Adrienne Graves buys 1,000 shares at $31.07 - Stock Titan
Harrow (HROW) director purchases 1,000 common shares at $31.00 price - Stock Titan
Harrow projects $71M-$81M Q2 revenue while reaffirming $350M-$365M 2026 outlook - MSN
[Form 4] HARROW, INC. Insider Trading Activity - Stock Titan
Mark Baum Buys Handful Of Shares In Harrow - Yahoo Finance
Harrow’s TRIESENCE Phase 3 Milestone Adds New Dimension To Growth Story - Sahm
Harrow Stock (HROW) Opinions on Q1 Earnings and Insider Buying - Quiver Quantitative
Harrow (HROW) Executives Make Notable Stock Purchases - GuruFocus
Why Harrow (HROW) Narrative Is Shifting As Analysts Recut Targets Yet Stay Positive - Yahoo Finance
Insider Buying: Mark Baum Acquires Additional Shares of Harrow I - GuruFocus
Harrow Insider Bought Shares Worth $302,000, According to a Recent SEC Filing - Moomoo
Harrow, Inc. CEO Mark L. Baum buys $302,000 in common stock - Investing.com India
Harrow president and CFO Andrew Boll buys $104,650 in stock By Investing.com - Investing.com Australia
Harrow president and CFO Andrew Boll buys $104,650 in stock - Investing.com India
Harrow Inc (HROW) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Harrow Inc 주식 (HROW) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| SILVERNAIL LAUREN P | Director |
May 18 '26 |
Buy |
31.00 |
1,000 |
31,000 |
1,000 |
| BAUM MARK L | CHIEF EXECUTIVE OFFICER |
May 14 '26 |
Buy |
30.20 |
10,000 |
302,000 |
2,996,130 |
| BOLL ANDREW R. | PRESIDENT AND CFO |
May 14 '26 |
Buy |
29.90 |
3,500 |
104,650 |
814,679 |
| Opaleye Management Inc. | 10% Owner |
Mar 04 '26 |
Sale |
39.67 |
138,263 |
5,485,184 |
59,428 |
| Opaleye Management Inc. | 10% Owner |
Mar 03 '26 |
Sale |
39.15 |
60,309 |
2,361,242 |
63,691 |
| Opaleye Management Inc. | 10% Owner |
Feb 27 '26 |
Sale |
54.18 |
5,000 |
270,900 |
65,000 |
| Opaleye Management Inc. | 10% Owner |
Jan 06 '26 |
Sale |
53.35 |
20,000 |
1,066,914 |
70,000 |
| BOLL ANDREW R. | PRESIDENT AND CFO |
Dec 12 '25 |
Option Exercise |
3.95 |
60,000 |
237,000 |
837,844 |
| BAUM MARK L | CHIEF EXECUTIVE OFFICER |
Dec 12 '25 |
Option Exercise |
3.95 |
180,000 |
711,000 |
3,066,124 |
| BAUM MARK L | CHIEF EXECUTIVE OFFICER |
Jul 21 '25 |
Option Exercise |
7.87 |
600,000 |
4,722,000 |
3,199,462 |
0.95%
1.13%
자본화:
|
볼륨(24시간):